Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Frank R. Ernst, Peri Barr, Riad Elmor & Schiffon L. Wong. (2017) Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Current Medical Research and Opinion 33:12, pages 2099-2106.
Read now
Read now
Articles from other publishers (3)
Bruce A.C. Cree, James D. Bowen, Hans-Peter Hartung, Patrick Vermersch, Bruce Hughes, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Megan Grosso, Daniel L. Jones & Thomas P. Leist. (2021) Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders 49, pages 102695.
Crossref
Crossref
Mark S Freedman, Thomas P Leist, Giancarlo Comi, Bruce AC Cree, Patricia K Coyle, Hans-Peter Hartung, Patrick Vermersch, Doris Damian & Fernando Dangond. (2017) The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:4, pages 205521731773280.
Crossref
Crossref
Carolina Obregon, Rajesh Kumar, Manuel Antonio Pascual, Giuseppe Vassalli & Déla Golshayan. (2017) Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. Frontiers in Immunology 8.
Crossref
Crossref